CDK6 and acute lymphoblastic leukemia: developed CDK4/6-targeting PROTACs that preferentially degrade CDK6 over CDK4 in Philadelphia-positive (Ph+) ALL cells, significantly suppressing S phase cell proliferation and inhibiting CDK6-regulated phospho-retinoblastoma (RB) protein and FOXM1 expression.